Lechlemer - Napo Pharmaceuticals
Alternative Names: NP 300; SB 300 - Napo PharmaceuticalsLatest Information Update: 25 Apr 2024
At a glance
- Originator Napo Pharmaceuticals
- Developer Jaguar Health; Napo Pharmaceuticals
- Class Antibacterials; Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies; Small molecules
- Mechanism of Action Chloride channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cholera
Most Recent Events
- 25 Apr 2024 Lechlemer is still in preclinical phase for Cholera in USA
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cholera in USA
- 01 Sep 2022 US FDA activates the company’s IND application for lechlemer and the US FDA concludes that Napo may proceed with its proposed phase I clinical trial